Half-life of estradiol in postmenopausal women. Gynecol Obstet Invest 1998;45:45-48.Ginsburg E S,Gao X,Shea B F,et al.Half -life of estradiol in postmenopausal women. Gynecologic and Obstetric Investigation . 1998Ginsburg ES, Gao X, Shea BF, Barbieri RL (1998) Half-life of estradiol in...
efficacy of DARE-HRT1. DARE-HRT1 is an intravaginal ring (IVR) that releases 17β2-estradiol (E2) with progesterone (P4) over 28 days. It is the first combination E2 and P4 IVR being developed for the treatment of vasomotor symptoms (VMS) in healthy postmenopausal women with an intact ...
More than 20 million women in the United States are between 45 and 55 years old—an age range at which many once were considered candidates for Premarin or other forms of hormone therapy. Although some women today choose to go on hormone therapy to relieve menopausal symptoms, it used to be...
Postmenopausal5.0–54.718.4–201 Clinical Application Althoughestradiolestimation is one of the most frequently requested hormone tests, its usefulness in the investigation of infertility in women is generally considered to be limited (seeFurtherReading). Aprogestogenchallenge is more helpful in establishing...
Estrogens protect against diet-induced obesity in women and female rodents. For example, a lack of estrogens in postmenopausal women is associated with an increased risk of weight gain, cardiovascular diseases, low-grade inflammation, and cancer. Estroge
biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more...
The results from this multicenter clinical trial18 suggest that DRSP/E2 combinations can improve health-related quality of life in postmenopausal women. The Women’s Health Questionnaire (WHQ) was administered at baseline and periodically throughout the study to evaluate a range of factors, ...
should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine whether treatment is still necessary. Adequate diagnostic measures, such ...
An estrogenic hormone, C18H24O2, that is produced by the ovaries and is the dominant naturally occurring estrogen in women between puberty and menopause. It is used to treat menopausal symptoms and other conditions. [estra-,estrogenic hormone(fromestrus) +di-+-ol.] ...
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should be considered only for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The lowest effective dose of ESTRACE has not been determined. ...